MA40202A - Anticorps anti-cd127 - Google Patents

Anticorps anti-cd127

Info

Publication number
MA40202A
MA40202A MA040202A MA40202A MA40202A MA 40202 A MA40202 A MA 40202A MA 040202 A MA040202 A MA 040202A MA 40202 A MA40202 A MA 40202A MA 40202 A MA40202 A MA 40202A
Authority
MA
Morocco
Prior art keywords
seq
antibodies
site
sequence
epitope
Prior art date
Application number
MA040202A
Other languages
English (en)
Inventor
Caroline Mary
Nicolas Poirier
Bernard Vanhove
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52434718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of MA40202A publication Critical patent/MA40202A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Cette invention concerne des anticorps dirigés contre cd127, la chaîne alpha du récepteur d'interleukine 7 (il-7) (il-7r), et qui ont des propriétés antagonistes vis-à-vis de l'interaction avec il-7-il-7r, peuvent manifester une activité cytotoxique contre les cellules positives à cd127 mais n'augmentent pas la maturation des cellules dendritiques (dc) induites par tslp, une cytokine utilisant également cd127 en tant que partie de son récepteur. En variante, ou en plus, ces anticorps n'induisent pas l'internalisation de cd127 et/ou inhibent l'internalisation de cd127 induite par l'il-7. Selon un autre aspect, cette invention concerne des anticorps qui reconnaissent un épitope cd127 humain comprenant des séquences provenant du site 2b de cd127, en particulier, l'épitope comprenant les séquences cd127 humaines du domaine d1 et du site 2b de cd127, en particulier l'épitope comprenant au moins une séquence provenant de d1 comprenant seq id no : 115 (en particulier comprenant seq id no :10) et/ou seq id no : 111 et/ou une séquence provenant du site 2b comprenant la séquence de seq id no 116 et éventuellement comprenant également seq id no : 117 (en particulier comprenant seq id no : 111). Les anticorps selon l'invention se prêtent à une utilisation visant à remédier à une affection diagnostiquée chez un patient humain qui résulte de la pathogenèse liée à la lymphopoïèse, quand les voies de signalisation de l'il-7 contribuent à ladite pathogenèse, notamment quand un accroissement de la maturation, plus précisément la sur-régulation des molécules co-stimulatrices, des cellules dendritiques n'est pas souhaitable.
MA040202A 2014-06-10 2015-06-10 Anticorps anti-cd127 MA40202A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462010117P 2014-06-10 2014-06-10
EP15305078.6A EP2955196A1 (fr) 2014-06-10 2015-01-23 Anticorps dirigés contre CD127

Publications (1)

Publication Number Publication Date
MA40202A true MA40202A (fr) 2017-04-19

Family

ID=52434718

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040202A MA40202A (fr) 2014-06-10 2015-06-10 Anticorps anti-cd127

Country Status (26)

Country Link
US (3) US10428152B2 (fr)
EP (2) EP2955196A1 (fr)
JP (2) JP7324565B2 (fr)
KR (1) KR102612930B1 (fr)
CN (1) CN106715471B (fr)
AP (1) AP2016009599A0 (fr)
AU (1) AU2015273532C1 (fr)
BR (1) BR112016028755B1 (fr)
CA (1) CA2950823A1 (fr)
CL (1) CL2016003172A1 (fr)
CR (1) CR20160576A (fr)
EA (1) EA039303B1 (fr)
HK (1) HK1231487A1 (fr)
IL (1) IL249449B (fr)
MA (1) MA40202A (fr)
MX (1) MX376066B (fr)
MY (1) MY190889A (fr)
NZ (1) NZ726932A (fr)
PE (1) PE20170324A1 (fr)
PH (1) PH12016502445A1 (fr)
RU (1) RU2734076C2 (fr)
SA (1) SA516380455B1 (fr)
SG (1) SG11201610036PA (fr)
TN (1) TN2016000528A1 (fr)
UA (1) UA125366C2 (fr)
WO (1) WO2015189302A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013124474A2 (fr) 2012-02-23 2013-08-29 Stage Cell Therapeutics Gmbh Isolement chromatographique de cellules et d'autres matériaux biologiques complexes
EP2955196A1 (fr) * 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
WO2016156468A1 (fr) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
CN107427577A (zh) 2015-03-31 2017-12-01 韦斯夸尔德有限公司 具有蛋白酶可切割接头的肽构建体
IL258844B2 (en) 2015-10-22 2024-03-01 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
WO2017125578A1 (fr) 2016-01-21 2017-07-27 Vhsquared Limited Polypeptides
RS59223B1 (sr) * 2016-02-29 2019-10-31 Ose Immunotherapeutics Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera
PE20191152A1 (es) 2016-12-09 2019-09-05 Ose Immunotherapeutics Anticuerpos y polipeptidos dirigidos contra cd127
EP3676292A1 (fr) * 2017-08-29 2020-07-08 OSE Immunotherapeutics Procédé et préparation permettant de trier des lymphocytes t effecteurs à l'aide d'anticorps anti-cd127 pour des applications en thérapie cellulaire
CN110117325B (zh) * 2018-03-09 2023-06-20 重庆市畜牧科学院 一种猪cd127多肽及其编码基因和应用
KR20230128134A (ko) 2019-01-22 2023-09-01 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
MX2021015762A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Composiciones.
MX2021015761A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
EP4142777A4 (fr) * 2020-04-27 2024-06-12 Memorial Sloan-Kettering Cancer Center Récepteur antigénique chimérique ciblant cd127 et utilisation associée
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
CA3250546A1 (fr) 2022-05-30 2023-12-07 Ose Immunotherapeutics Biomarqueurs d’activité de modulateur d’il7r
CN115925955B (zh) * 2022-12-30 2025-09-26 浙江正熙生物技术有限公司 一种抗cd127抗体及其制备方法和应用
EP4646274A1 (fr) 2023-01-06 2025-11-12 Twain Therapeutics Pte. Ltd. Molécules de liaison à l'antigène
EP4455308A1 (fr) 2023-04-24 2024-10-30 Les Laboratoires Servier Signatures géniques il-7r
CN121666232A (zh) 2023-05-31 2026-03-13 开普斯坦治疗公司 脂质纳米颗粒制剂和组合物
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
WO2025076127A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025089399A1 (fr) * 2023-10-26 2025-05-01 国立研究開発法人国立がん研究センター Anticorps dirigé contre le récepteur de l'interleukine-7 (il-7r), et conjugué anticorps-médicament (adc) comprenant ledit anticorps
WO2025179294A2 (fr) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Amplification d'ingénierie immunitaire
WO2025202213A1 (fr) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Nanoparticule lipidique chargée d'agent antitumoral et fonctionnalisée pour cibler des cellules immosuppressives
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
CN118638236B (zh) * 2024-07-09 2025-03-14 武汉爱博泰克生物科技有限公司 抗人cd127蛋白的抗体、抗体偶联物及其应用
WO2026022216A1 (fr) 2024-07-23 2026-01-29 Ose Immunotherapeutics Utilisations d'anticorps anti-cd127 dans le traitement de maladies intestinales inflammatoires
WO2026033132A1 (fr) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Molécules de liaison à l'antigène

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2007266450A1 (en) 2006-05-31 2007-12-06 The Regents Of The University Of California CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs
EP1930342B1 (fr) 2006-12-04 2012-01-25 Institut Pasteur OB-fold utilisé en tant que base pour l'ingénierie de nouveaux liants spécifiques
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2010085643A1 (fr) 2009-01-22 2010-07-29 University Of Miami Ciblage de la signalisation il-7 à des fins de traitement de la sclérose en plaques et d'autres troubles dépendant de la signalisation il-7
US8940303B2 (en) * 2010-01-28 2015-01-27 Glaxo Group Limited CD127 binding proteins
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
EP2583980A1 (fr) 2011-10-19 2013-04-24 Effimune Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments
EP2955196A1 (fr) * 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
RS59223B1 (sr) 2016-02-29 2019-10-31 Ose Immunotherapeutics Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera

Also Published As

Publication number Publication date
IL249449A0 (en) 2017-02-28
HK1231487A1 (zh) 2017-12-22
RU2016151265A (ru) 2018-07-18
IL249449B (en) 2020-06-30
EP2955196A1 (fr) 2015-12-16
WO2015189302A1 (fr) 2015-12-17
US20190382497A1 (en) 2019-12-19
AU2015273532C1 (en) 2021-07-15
JP2017522903A (ja) 2017-08-17
NZ726932A (en) 2022-02-25
EP3155014A1 (fr) 2017-04-19
RU2734076C2 (ru) 2020-10-12
US20230340133A1 (en) 2023-10-26
CN106715471B (zh) 2021-04-09
PH12016502445A1 (en) 2017-03-06
MY190889A (en) 2022-05-17
AU2015273532A1 (en) 2016-12-22
RU2016151265A3 (fr) 2019-02-08
KR102612930B1 (ko) 2023-12-13
CR20160576A (es) 2017-05-08
US12371502B2 (en) 2025-07-29
PE20170324A1 (es) 2017-04-01
SG11201610036PA (en) 2016-12-29
MX376066B (es) 2025-03-07
AU2015273532B2 (en) 2021-03-04
BR112016028755A2 (pt) 2017-11-14
SA516380455B1 (ar) 2020-12-22
EA039303B1 (ru) 2022-01-11
KR20170019417A (ko) 2017-02-21
US11440964B2 (en) 2022-09-13
EA201692460A1 (ru) 2017-04-28
TN2016000528A1 (en) 2018-04-04
AP2016009599A0 (en) 2016-11-30
JP7324565B2 (ja) 2023-08-10
JP2021184731A (ja) 2021-12-09
MX2016016236A (es) 2017-07-05
BR112016028755B1 (pt) 2024-01-16
UA125366C2 (uk) 2022-03-02
US20170129959A1 (en) 2017-05-11
CL2016003172A1 (es) 2017-07-14
US10428152B2 (en) 2019-10-01
CA2950823A1 (fr) 2015-12-17
CN106715471A (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
PH12016502445A1 (en) Antibodies directed against cd127
SV2018005614A (es) Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias
MX2019009654A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
UA113397C2 (xx) Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
EP4378536A3 (fr) Inhibiteurs peptidiques oraux du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies intestinales inflammatoires
UA107827C2 (xx) Антитіло до cd40
NZ711946A (en) Newcastle disease viruses and uses thereof
GT201300150A (es) Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer
ECSP11011019A (es) Antagonistas del receptor de orexina de isonicotinamida
MY153078A (en) Compositions and methods for increasing muscle growth
PH12020552235A1 (en) Anti-cd40 antibodies for use in treating autoimmune disease
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
EA201390813A1 (ru) Антитела и их применение
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
EA201890149A1 (ru) Композиции криопреципитатов и способы их получения
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
TH171839A (th) แอนติบอดีที่มุ่งต้าน cd127
AR104621A1 (es) TRATAMIENTO DE LA b-TALASEMIA POR EL USO DE TRAMPAS DE LIGANDO ActRII
ECSP10010250A (es) Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad
DOP2010000147A (es) Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad
HK1228445A1 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
CU20130079A7 (es) Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer
CR11498A (es) Metodos para el tratamiento de la obesidad y enfermedades y desordenes relacionados a la obesidad
UA102437C2 (ru) Композиции и способы для усиления мышечного роста